Global markets have experienced a turbulent week, with major indices like the S&P 500 and Dow Jones Industrial Average closing lower amid geopolitical tensions and economic updates. In such volatile times, investors often seek opportunities in less conventional areas of the market, such as penny stocks. Although the term 'penny stock' may seem outdated, it still represents smaller or emerging companies that can offer substantial value when backed by strong financials.

Top 10 Penny Stocks Globally

Name Share Price Market Cap Financial Health Rating Lever Style (SEHK:1346) HK$1.42 HK$878.3M ★★★★★★ Foresight Group Holdings (LSE:FSG) £4.28 £489.57M ★★★★★★ IVE Group (ASX:IGL) A$2.99 A$473.21M ★★★★★☆ TK Group (Holdings) (SEHK:2283) HK$2.48 HK$2.04B ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.60 SEK269.95M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD3.35 SGD13.18B ★★★★★☆ Integrated Diagnostics Holdings (LSE:IDHC) $0.63 $366.24M ★★★★★☆ EDU Holdings (ASX:EDU) A$0.76 A$107.95M ★★★★★☆ REDtone Digital Berhad (KLSE:REDTONE) MYR0.37 MYR285.99M ★★★★★☆ Begbies Traynor Group (AIM:BEG) £1.20 £193.11M ★★★★★☆

Click here to see the full list of 3,521 stocks from our Global Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Yonghe Medical Group

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Yonghe Medical Group Co., Ltd. operates in China, offering hair-related healthcare services, with a market cap of approximately HK$1.04 billion.

Operations: The company generates revenue primarily from the provision of hair transplant services, amounting to CN¥1.77 billion.

Market Cap: HK$1.04B

Yonghe Medical Group, operating in the hair-related healthcare sector in China, is currently unprofitable but maintains a strong financial position with more cash than debt and short-term assets exceeding its liabilities. The company trades significantly below estimated fair value and offers good relative value compared to peers. Despite negative returns on equity, Yonghe has a sufficient cash runway for over three years, supported by positive free cash flow. Earnings are forecasted to grow substantially at 157.85% annually. The management team and board are experienced, with tenures averaging over four years each.

Take a closer look at Yonghe Medical Group's potential here in our financial health report. Gain insights into Yonghe Medical Group's outlook and expected performance with our report on the company's earnings estimates.SEHK:2279 Debt to Equity History and Analysis as at Jan 2026

HG Metal Manufacturing

Simply Wall St Financial Health Rating: ★★★★★★

Overview: HG Metal Manufacturing Limited is an investment holding company that primarily trades in steel products across Indonesia, Malaysia, Myanmar, and Singapore with a market cap of SGD182.70 million.



Operations: The company's revenue is derived from two main segments: Trading, which contributes SGD56.39 million, and Manufacturing, accounting for SGD169.49 million.

Market Cap: SGD182.7M

HG Metal Manufacturing Limited demonstrates financial stability with its short-term assets surpassing both long-term and short-term liabilities, and a debt-to-equity ratio that has decreased significantly over five years. The company reported sales of SGD 130.27 million for the nine months ending September 2025, with net income reaching SGD 7.34 million, reflecting a robust earnings growth of 28.3% over the past year compared to its five-year average. While trading well below estimated fair value, HG Metal's dividend history is unstable but currently proposes a tax-exempt dividend of SGD 0.015 per share payable in February 2026.

Navigate through the intricacies of HG Metal Manufacturing with our comprehensive balance sheet health report here. Gain insights into HG Metal Manufacturing's historical outcomes by reviewing our past performance report.SGX:BTG Financial Position Analysis as at Jan 2026

Dezhan Healthcare

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Dezhan Healthcare Company Limited focuses on the research, development, manufacture, and sale of cardiovascular and cerebrovascular drugs in China with a market cap of CN¥7.95 billion.

Operations: Currently, there are no reported revenue segments for the company.

Market Cap: CN¥7.95B

Dezhan Healthcare, with a market cap of CN¥7.95 billion, focuses on cardiovascular and cerebrovascular drugs in China but remains pre-revenue. The company is unprofitable with losses increasing at 43.6% annually over five years. Despite this, Dezhan's short-term assets of CN¥3.2 billion significantly exceed both its short-term and long-term liabilities, suggesting strong liquidity management. Additionally, the debt level is well-managed as cash surpasses total debt and operating cash flow covers 32.1% of the debt obligations. Management demonstrates experience with an average tenure of 2.4 years, while the board averages 4.4 years in tenure.

Click to explore a detailed breakdown of our findings in Dezhan Healthcare's financial health report. Review our historical performance report to gain insights into Dezhan Healthcare's track record.SZSE:000813 Financial Position Analysis as at Jan 2026

Key Takeaways

Explore the 3,521 names from our  Global Penny Stocks screener here. Searching for a Fresh Perspective? Uncover 14 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:2279 SGX:BTG and SZSE:000813.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]